SG11202111473UA - Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof - Google Patents

Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof

Info

Publication number
SG11202111473UA
SG11202111473UA SG11202111473UA SG11202111473UA SG11202111473UA SG 11202111473U A SG11202111473U A SG 11202111473UA SG 11202111473U A SG11202111473U A SG 11202111473UA SG 11202111473U A SG11202111473U A SG 11202111473UA SG 11202111473U A SG11202111473U A SG 11202111473UA
Authority
SG
Singapore
Prior art keywords
assessing
disease
risk
methods
detection kit
Prior art date
Application number
SG11202111473UA
Inventor
Wen-Hung Chung
Shuen-Iu Hung
Chuang-Wei Wang
Original Assignee
Chang Gung Memorial Hospital Linkou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chang Gung Memorial Hospital Linkou filed Critical Chang Gung Memorial Hospital Linkou
Publication of SG11202111473UA publication Critical patent/SG11202111473UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11202111473UA 2019-05-06 2019-05-06 Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof SG11202111473UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/085639 WO2020223867A1 (en) 2019-05-06 2019-05-06 Method for assessing risk of severe cutaneous adverse drug reactions caused by disease-modulating antirheumatic drugs, test kit thereof, and use thereof

Publications (1)

Publication Number Publication Date
SG11202111473UA true SG11202111473UA (en) 2021-11-29

Family

ID=73050684

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111473UA SG11202111473UA (en) 2019-05-06 2019-05-06 Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof

Country Status (7)

Country Link
US (1) US20220259655A1 (en)
JP (1) JP7334263B2 (en)
KR (1) KR20210149135A (en)
CN (1) CN112513294A (en)
CA (1) CA3137521A1 (en)
SG (1) SG11202111473UA (en)
WO (1) WO2020223867A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470513B2 (en) 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
EP2016198B1 (en) * 2006-05-11 2013-05-01 Academia Sinica Method for predicting a risk of adverse drug reactions by determination of hla-b 1502
CN102108382A (en) * 2009-12-23 2011-06-29 上海主健生物工程有限公司 Genetic testing for risk of causing serious adverse reactions of skin of carbamazepine
CN105039579B (en) * 2011-06-23 2018-10-02 长庚医疗财团法人基隆长庚纪念医院 Cause the method for drug anaphylaxis with HLA allele assessment antiepileptic phenytoinum naticum
CN104818316B (en) * 2013-11-28 2018-09-21 复旦大学 Human leukocyte antigen gene detecting kit for dermal drug adverse reaction caused by screening salicylazosulfapyridine
CN107574235A (en) 2017-10-25 2018-01-12 广州和康医疗技术有限公司 A kind of salicylazosulfapyridine adverse reaction risk SNP site detection method and kit
CN109355358A (en) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 A kind of kit and method rapidly and efficiently detecting drug induccd skin adverse reaction related gene polymorphism

Also Published As

Publication number Publication date
KR20210149135A (en) 2021-12-08
CA3137521A1 (en) 2020-11-12
JP2022531136A (en) 2022-07-06
JP7334263B2 (en) 2023-08-28
US20220259655A1 (en) 2022-08-18
CN112513294A (en) 2021-03-16
WO2020223867A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
IL270864A (en) Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders
GB2591361B (en) Methods and systems for determining a physiological or biological state or condition of a subject
IL283845A (en) Methods for detecting disease using analysis of rna
SG11202007871RA (en) Systems and methods for detection of residual disease
EP3289082A4 (en) Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens
WO2015176066A3 (en) Lpa-associated protein and rna expression
FR3023617B1 (en) NON - INVASIVE DEVICE FOR DETERMINING THE FERTILITY AND / OR SEX OF AN EGG AND CORRESPONDING METHOD.
IL288098A (en) Methods and systems for detecting residual disease
WO2016126972A8 (en) Mutant smoothened and methods of using the same
MX2020007771A (en) Methods for colon cancer detection and treatment monitoring.
EP3784397A4 (en) New apparatus and methods for disease detection
MX2021003764A (en) Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia.
MA50098A (en) METHODS FOR DETECTION OF FOLATE RECEPTOR 1 IN A SAMPLE FROM A PATIENT
MX2016009450A (en) Novel assay to detect human periostin.
EP4081345A4 (en) Analyte sensing system and cartridge thereof
BR112016029935A2 (en) anti-brdu antibodies, complex, pharmaceutical formulation and antibody use?
IL279377A (en) Methods for assessment and early detection of stress, selecting and monitoring treatment, and new use for drugs
EP3869198A3 (en) Reagents and methods for breast cancer detection
FR3017703B1 (en) METHOD AND SYSTEM FOR DETERMINING THE COMPATIBILITY OF ANGULAR GUIDANCE WITH AN APPROACH
SG11202111473UA (en) Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof
EP4101379C0 (en) Biosensor capsule and system
WO2015120075A3 (en) Mutant smoothened and methods of using the same
EP3685178A4 (en) Systems and methods for detecting small physiological or pathological changes using high resolution magnetic resonance imaging
SG11202003391XA (en) Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof
IL272484A (en) Systems and methods for improving disease diagnosis using measured analytes